The DIS3L Knockout NCI-H1299 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the DIS3L gene in the NCI-H1299 human non-small cell lung cancer (NSCLC) cell line. This loss-of-function model provides a valuable tool for investigating DIS3L-dependent RNA metabolism and its implications in cancer biology. As a polyclonal population, the cells harbor heterogeneous gene disruptions introduced by CRISPR/Cas9, enabling the study of DIS3L deficiency without clonal selection artifacts.
The NCI-H1299 cell line was originally established from the lymph node metastasis of a 43-year-old male patient with lung adenocarcinoma. These adherent epithelial cells are a widely employed model for NSCLC research, characterized by their metastatic origin and genetic alterations, including TP53 mutations, that drive tumor progression. NCI-H1299 cells are routinely used to assess oncogenic signaling, drug sensitivity, and mechanisms of invasion, making them a relevant host for studying the role of RNA processing factors in cancer.
DIS3L functions as the catalytic subunit of the cytoplasmic RNA exosome, a multi-protein complex responsible for 3′-5′ exoribonucleolytic processing and degradation of diverse RNA substrates. It operates in concert with nine core exosome subunits (EXOSC2?CEXOSC10) and is activated by the RNA helicase SKIV2L2 (MTR4), which unwinds structured RNAs for channeling into the exosome barrel. DIS3L is transcriptionally regulated by the oncoprotein MYC, linking its expression to cellular growth and stress signals. Its downstream targets include mRNAs, rRNAs, and non-coding RNAs, and it plays a critical role in RNA surveillance pathways such as nonsense-mediated decay and constitutive RNA turnover. Disruption of DIS3L therefore leads to accumulation of aberrant transcripts and widespread transcriptomic alterations.
In the context of NCI-H1299 cells, DIS3L knockout is predicted to impair cytoplasmic RNA decay, resulting in the stabilization of normally short-lived transcripts and potential dysregulation of gene expression programs that control proliferation, apoptosis, and metastasis. Given the oncogenic role of MYC in lung adenocarcinoma and the reliance of cancer cells on robust RNA processing, this knockout model may reveal vulnerabilities associated with RNA exosome dysfunction. Furthermore, the polyclonal nature of the knockout mimics the heterogeneity of tumor cell populations, allowing researchers to examine how DIS3L loss influences cancer-relevant phenotypes in a more physiologically relevant setting.
Typical applications of the DIS3L Knockout NCI-H1299 Polyclonal Cells include RNA biology studies aimed at dissecting exosome-mediated decay pathways, functional analysis of DIS3L in NSCLC progression, and drug target validation efforts focused on RNA metabolism. These cells are compatible with a range of downstream assays, including RNA-seq for transcriptome-wide analysis, RT-qPCR and northern blotting for specific RNA quantification, western blotting for protein-level assessment of exosome subunits, and cell viability or RNA stability assays to phenotype the knockout effects. For further details or to inquire about this product, please contact Ascent Research.
